Analyst coverage opens up on Acutus Medical (AFIB +14.1%).
William Blair launches the online marketplace stock with a Outperform rating. Analyst Margaret Kaczor estimates sales of $11.8M in 2020, $55M in 2021, and $125.4M in 2022; he believes better outcomes—particularly for hard-to-treat cases—a better patient/care team experience, and a lower cost to treat should lead to a 120% sales CAGR through 2022.
“Acutus is poised to take share and expand the $5.7B global cardiac ablation market,” Kaczor added.
JPMorgan Chase sets an Overweight rating and price target of $39. Buy ratings have been initiated by Bank of America (PT, 38), BTIG Research (PT, 40) and BofA Securities (PT, 38). Cautious ratings are in from Canaccord Genuity (Hold).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.